Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kontafarma China Holdings Ltd ( (HK:1312) ) just unveiled an update.
Kontafarma China Holdings Ltd has set out the formal terms of reference for its board remuneration committee, which is composed entirely of non-executive directors with a majority of independent non-executive directors and chaired by an independent director. The company secretary serves as committee secretary, and the committee is required to meet at least annually, with provisions for additional meetings and participation via teleconference. The new framework empowers the committee to recommend and oversee policies on remuneration structure and levels for directors and senior management, including salaries, benefits, pensions and termination compensation, with reference to corporate objectives, peer company pay and internal conditions across the group. By codifying these responsibilities and procedures, Kontafarma aims to ensure a formal, transparent and competitive remuneration regime that helps attract and retain leadership while avoiding excessive pay, bolstering its corporate governance standards for stakeholders.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
More about Kontafarma China Holdings Ltd
Average Trading Volume: 1,707,185
Technical Sentiment Signal: Sell
Current Market Cap: HK$156.2M
For detailed information about 1312 stock, go to TipRanks’ Stock Analysis page.